

Colorado Consortium for Prescription Drug Abuse Prevention

PDMP Work Group Meeting Minutes

September 13, 2018 - School of Pharmacy & by GoToMeeting

Present:

Jason Hoppe, DO (Co-chair) University of Colorado
Nathan Batchelder, (Co-chair) DORA
Katie Olson, CDPHE
Barbara Gabella, CDPHE
Andres Guerrero, CDPHE
Elizabeth S. Grace, MD, Center for Personalized Education for Physicians
Barbara Gabella, CDPHE
Allison Rosenthal, CDPHE
Marjorie Zimdars-Orthman, Lay Person
Rob Valuck, Consortium
Gina Olberding, Consortium
Susanna Cooper, Consortium
Tyler Payne, Consortium
Jessica Eaddy, Consortium
Rosemarie MacDowell, Consortium

Absent: Chris Gassen, DORA; Marta Brooks, Pharmacist; Melanie Snyder, Attorney General's Office; Janet VanOsterbridge; Talia Brown, Boulder County Health; Mary Brown, Quality Health Network (retired); Cheryl Hara, Center for Personalized Education for Physicians; Kristi Mihok, Walgreens; Robert Lodge, Department of Health Care Policy & Financing; Gregg Hanson, Walgreens; Brett Kessler, Colorado Dental Association; Laura Borgelt, UC School of Pharmacy; Janetta Iwanicki, Rocky Mountain Poison & Drug Center; Joe Liber, Kmart and ADMHN Pharmacy; Wendy Anderson, Consultant, Affiliated Monitors, Inc.; Sen. John Kefalas, Colorado Senate; Rep. Dianne Primavera, Colorado House of Representatives; Jennifer Ziouras, MD, Kaiser Permanente; Judy Margolis, MD; Dawn Fosket, Lay Person; Michelle Mack, Express Scripts; Katy Brown, Telligen; Kevin Vanderveen, MD, Kaiser Permanente; Hayes Veeneman, Lay Person; Robert Perry, MD; Marc Lassaux, QHN; Kate Horle, CORHIO; Kara Leach, MD; Timothy Rodgers, MD, Rocky Mountain Senior Care; Edie Son, Pinnacol; Kara Leach, MD; Tom Denberg, MD, Pinnacol; Helen Harris, El Paso County Public Health; Carrie Paykoc, State Health IT Coordinator; Tom Denver, Pinnacol; Jose Tomas Prieto, Denver Health; Heather Deis, Denver Health; Bernadette Albanese, MD; Maria Butler, CDPHE; Lawrence Wall, Jr., Wall Consulting; Stephanie Stewart, UC Denver; Whit Oyler, Consortium; Michael Davidson, Consortium; Eileen Forlenza, State Government/Arizona, Colorado, New Mexico, Wyoming; John Turtle, Pharmacist; Erin Ferries, MPH, Humana; Will Swann, MPA, PhD, UC Denver; Mark Davis, MPA, PhD, West Chester University; Nagy Ramzy, Retired Pharmacist; Lina Brou, UC Denver; Quig Li, Epidemiologist; Will Swann, UC Denver; Terri Schreiber, Schreiber Consulting; Justin Aubert, Quality Health Network; Lindsey Myers, CDPHE

Co-Chair Jason Hoppe called the meeting to order at 3:35 p.m. and asked if anyone had a questions regarding the August meeting minutes.

Marjorie Zimdars-Orthman asked for clarification of the following sentence on page two: "Credible arguments could be made for statutorily authorizing PDMP enhancements (minus a fiscal note) that

could justify tracking naloxone, gabapentin, and other non-controlled drugs.” Clarification was provided by Dr. Hoppe, who said he would also be showing a slide to further explain the tracking system.

Approval of Minutes:

A motion was made to approve the July 2018 work group meeting minutes. Motion passed.

DORA Updates (Nathan Batchelder):

A stakeholder meeting was held the previous week regarding the revised guidelines for opioid prescribing detailed in SB 22 (PDMP query mandate and prescribing limits). More than 100 people from across the state attended the online meeting. DORA is continuing stakeholder outreach, and they are still assessing whether or not the guidelines will need to be changed. The meeting also provided an excellent forum for pharmacists and prescribers to communicate with each other and potentially work more closely together in the future.

DORA’s executive director Marguerite Salazar has also issued a research request in the form of a letter that Nathan will email to committee members. Nathan explained the statute contains a requirement for DORA’s executive director to consult with and request assistance from the Consortium (as the PDMP task force) on all matters relating to the PDMP. This includes research assistance, consultation, and guidance. This fiscal year’s task request involves 1) carrying over last year’s research and metrics analysis request, including measuring the success of the PDMP (other than utilization) and reviewing other states’ best practices; 2) a study of statewide HIE integration and the potential health outcomes, which would also include a cost/benefit analysis.

Jason Hoppe reported that a BJA grant is pending and funding is likely. He also mentioned that the level of analysis requested by DORA for HIE integration might require locating someone with enough expertise to carry out the task. The grant funding could be used to fund a position. He also mentioned that there is some patient outcome tracking at the university that might prove helpful when conducting the analyses. Jose Prieto at Denver Health might be of assistance. Jason said they also have a cross-analysis employee in emergency medicine who might also help. Nathan emphasized that the work would be a team effort between DORA and the Consortium. Katie Olson asked if DORA had looked into discussing costs with vendors. She mentioned that the State of Washington’s entire integration cost was under \$20,000 per year.

Colorado PDMP Data Profile Updates:

Jason Hoppe presented slides submitted by Maria Butler (copy attached). Updates included the following:

- PDMP surveillance
- Number of users and patient searches by provider role
- Number of controlled substances dispensed by provider role (more than 4 million prescriptions were written by physicians)
- Prescriptions dispensed by drug class
- Characteristics of opioid prescriptions dispensed
- High risk prescribing practices and patient behaviors
- Opioid prescriptions by county designation and drug class

Jason also presented slides from the PDMP TTAC website, which showed the following information by state:

- Release of PDMP data for epidemiological research or educational purposes
- Naloxone tracking
- PDMP by operating state agency type, i.e., pharmacy board, department of health, law enforcement, professional licensing agency, substance abuse agency, consumer protection agency (Nathan mentioned that DORA functions more as the “umbrella” licensing agency rather than a pharmacy board)
- PDMP data collection frequency (majority by next business day)
- PDMP primary source of funding (most states’ funding comes from licensing fees)
- Drugs monitored by the PDMP
- PDMP number of staff (operations, technical, analytical, other). Colorado has one dedicated full time employee to administer the day-to-day PDMP operations. There are other employees also working on the PDMP, but not on a dedicated basis

CDPHE Update (Katie Olson and Andres Guerrero):

Funding has been obtained through crisis emergency preparedness. A portion of the funding will be used to expand HIE integration through CORHIO and QHN. The funding will also be used to expand the Opi Safe project. Katie noted that the State of Washington changed their statute so they could query their PDMP at the facility level, i.e., a hospital can have one license for all physicians to utilize, which is also integrated to provide an audit trail on the EHR side. Jason said the Colorado statute does not allow this. Katie agreed it would require a policy change. BlockMedx, an e-prescribing and analytics system, was briefly discussed.

Adjournment and Next Meeting:

The meeting adjourned at 4:22 p.m. The next meeting will be held on Thursday, November 8th from 3:30 – 4:30 p.m. in SSPPS Room 3001 and by GoToMeeting.